Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind, placebo-controlled, randomized trial.
Some studies have demonstrated the beneficial effects of Spirulina maxima (Arthrospira maxima) consumption on glycemic, lipid, and blood pressure parameters. The aim of this study was to investigate the effect of Spirulina maxima on body weight, blood pressure, and endothelial function. In this randomized double-blind placebo-controlled trial, 40 patients with hypertension but lacking evidence of cardiovascular disease were enrolled to receive daily either 2.0 g Hawaiian spirulina or placebo for three months. Anthropometric parameters, systolic blood pressure (SBP), diastolic blood pressure (DBP), and stiffness index (SI) using digital plethysmography were measured before and after the intervention. After three months, there was no change in body mass index (BMI) or weight in either the spirulina or the placebo group. However, a significant reduction in SBP and SI was observed. The patients in the spirulina group showed significant reductions in BMI (26.9 ± 3.1 vs. 25.0 ± 2.7 kg/m(2), p = 0.0032), weight (75.5 ± 11.8 vs. 70.5 ± 10.3 kg, p < 0.001), SBP (149 ± 7 vs. 143 ± 9 mmHg, p = 0.0023), and SI (7.2 ± 0.6 vs. 6.9 ± 0.7 m/s, p < 0.001). The tested parameters did not change in the placebo group. This study demonstrates that three months of regular consumption of Spirulina maxima not only improves BMI and weight but also results in improvements in blood pressure and endothelial function spirulina in overweight patients with hypertension but lacking evidence of cardiovascular disease.